SEC Form 8-K Summary
Registrant: Consonance-HFW Acquisition Corp. (CHFW), in connection with its proposed business combination with Surrozen, Inc.
Reporting date: May 13, 2021; the report was signed May 14, 2021. The filing is a current report and does not present operating results for Surrozen or CHFW.
Business Context and Reporting Period
CHFW is a special purpose acquisition company pursuing an initial business combination with Surrozen. The filing addresses accounting treatment for CHFW’s public and private placement warrants and provides an update on the proposed transaction.
Financial Metrics and Liquidity
- The filing does not provide current revenue, profit, cash flow, margin, debt, liquidity, or other operating financial metrics.
- CHFW previously classified its public and private placement warrants as equity.
- Following the SEC’s April 12, 2021 guidance, CHFW concluded that the warrants should instead be classified as derivative liabilities under ASC 815 and measured at fair value, with changes in fair value recognized in earnings.
- The filing does not provide the finalized warrant valuation or the quantified effect on assets, liabilities, equity, net income, or accumulated deficit.
Material Changes Versus Prior Periods
Management and the Audit Committee determined on May 13, 2021 that CHFW’s previously issued financial statements for the following periods should no longer be relied upon:
- The audited balance sheet related to the November 23, 2020 initial public offering.
- The unaudited period from inception on August 21, 2020 through September 30, 2020.
- The audited year ended December 31, 2020 financial statements filed in the Form 10-K and Form 10-K/A.
CHFW intends to amend its 2020 Form 10-K and Form 10-K/A to reflect the warrant reclassification and related fair-value adjustments. The terms and number of warrants have not changed. The restatement is required for accounting alignment with the SEC’s guidance and is not described as a change in management’s expectations regarding the business prospects of CHFW or Surrozen.
Guidance, Outlook, Risks, and Unusual Items
- CHFW expects to schedule an extraordinary general meeting for shareholder consideration of the business combination and related proposals.
- CHFW intends to file a Form S-4 containing a proxy statement and prospectus. The transaction remains subject to regulatory review, shareholder approvals, and other closing conditions.
- The company stated that it does not expect the warrant restatement to materially affect shareholders’ consideration of the proposed business combination, although the filing does not quantify its impact.
- Key risks include failure to complete the transaction, shareholder redemptions, failure to obtain required approvals, competing transaction proposals, litigation, transaction costs, integration and growth challenges, retention of key employees, and inability to maintain a post-combination Nasdaq listing.
- Forward-looking statements are subject to substantial uncertainty, including risks related to the warrant accounting and the ability to realize anticipated benefits of the business combination.
Important Facts for Investors to Verify
- The amended 2020 Form 10-K and Form 10-K/A, including the final warrant valuation and quantified restatement effects.
- The Form S-4, definitive proxy statement/prospectus, transaction terms, pro forma financial information, and required approvals.
- The amount of shareholder redemption requests and the resulting cash available to the combined company.
- Whether the business combination closes and whether the combined company obtains and maintains Nasdaq listing.
- The financial statement effects of recurring fair-value changes in the warrant liabilities after reclassification.